Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Added: 3 months ago Source:  Radcliffe Cardiology
The US Food and Drug Administration (FDA) has approved the non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) finerenone (Kerendia, Bayer). The new indication is for adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40% to reduce the risk of cardiovascular death, hospitalisation for heart failure, and urgent heart failure visits.¹ The… View more
Author(s): Jozine ter Maaten Added: 2 years ago
ESC 2023 — Dr Jozine Ter Maaten (University Medical Centre Groningen, NL) joins us to outline the findings from the PUSH-AHF Study (NCT04606927). PUSH-AHF (University Medical Center Groningen) aimed to assess the effect of natriuresis-guided therapy in patients with acute heart failure to improve diagnostic response, decongestion and clinical outcomes. 310 patients with a primary diagnosis of… View more
Research Area(s) / Expertise:

Heart Failure

Job title: Cardiologist
Dr Jozine ter Maaten is a cardiologist at the University Medical Center Groningen, specializing in acute heart failure. Her research focuses on understanding congestion and improving diuretic response and outcomes in patients with this condition. Dr ter Maaten completed her PhD on 'Diuretic response and renal biomarkers in heart failure' in 2016 and has since been actively involved in research… View more
Added: 3 months ago Source:  Radcliffe Cardiology
A new nationwide cohort study from France suggests that a simple risk stratification tool based on administrative data could help tailor cardiologist follow-up for patients with heart failure (HF), potentially improving survival and optimising resource use. The study found that 40% of patients with HF do not have an annual cardiology consultation, regardless of their disease severity.¹The French… View more